Segall Bryant & Hamill LLC Purchases 83,654 Shares of Protagonist Therapeutics, Inc. $PTGX

Segall Bryant & Hamill LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 64.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 212,714 shares of the company’s stock after buying an additional 83,654 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Protagonist Therapeutics were worth $22,420,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NEXTBio Capital Management LP bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth $20,055,000. Jennison Associates LLC bought a new position in Protagonist Therapeutics in the fourth quarter valued at about $28,924,000. Keystone Investors PTE Ltd. acquired a new position in Protagonist Therapeutics during the fourth quarter worth about $2,305,000. Clearbridge Investments LLC acquired a new position in Protagonist Therapeutics during the fourth quarter worth about $42,783,000. Finally, Eagle Health Investments LP acquired a new position in Protagonist Therapeutics during the fourth quarter worth about $5,005,000. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX opened at $136.64 on Friday. Protagonist Therapeutics, Inc. has a 52 week low of $50.49 and a 52 week high of $143.29. The firm has a market cap of $8.79 billion, a PE ratio of -75.49 and a beta of 1.79. The firm’s fifty day moving average is $120.38 and its 200-day moving average is $103.23.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. The business had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Bryan Giraudo sold 6,000 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $100.00, for a total value of $600,000.00. Following the sale, the director owned 31,825 shares in the company, valued at approximately $3,182,500. The trade was a 15.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director William D. Waddill sold 9,000 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. The trade was a 53.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 161,130 shares of company stock worth $16,355,220. Insiders own 5.19% of the company’s stock.

Wall Street Analysts Forecast Growth

PTGX has been the topic of a number of research analyst reports. Wolfe Research initiated coverage on shares of Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price target on the stock. Truist Financial upped their price objective on shares of Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Johnson Rice set a $165.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, July 17th. Wedbush increased their price objective on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $110.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $123.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.